AbbVie Inc. (ABBV)
February Dividends With 4 Raises: 1.6% Up To 14.5%
Rose's Income Garden portfolio reached an all-time high, with forward yield dipping slightly to 6% as portfolio value increased. Mastercard stands out with a 14.5% dividend raise, attractive valuation (P/E 26.41 vs. 5-year 34.81x), and robust earnings growth, making it a core hold. Bristol Myers Squibb and AbbVie are both considered holds due to disappointing or modest dividend raises and valuations above historical norms.
The High Dividend Yield Bull Market: 3 Compelling 6% Yields
High-yield stocks are outperforming, with a clear rotation from growth to value driving strong returns for dividend-focused investors. Safe, high-yielding companies are still trading at discounts. These 3 are in the process of rerating, providing an appealing position to initiate a position.
Best Dividend Aristocrats For March 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
Merck & Co. (MRK) is upgraded to buy, driven by improving dividend cushion ratio (DCR) and robust FQ4 2025 earnings recovery. MRK's dividend safety strengthens, with a projected DCR of 2.57x for 2026, surpassing both its historical average and ABBV's outlook. AbbVie (ABBV) maintains strong results but faces DCR pressure from CAPEX plans, with a projected 2.19x DCR in 2026.
Here's Why AbbVie (ABBV) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.
Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?
AbbVie ABBV announced encouraging fourth-quarter and full-year 2025 results earlier this month that beat expectations. A major portion of the company's top-line growth came from its newer immunology medicines, Rinvoq and Skyrizi, which not only mitigated the impact of continued erosion in legacy drug Humira but also reaffirmed their role as AbbVie's key growth drivers.
The Zacks Analyst Blog AbbVie, RTX, International Business Machines, EVI Industries, and Rocky Mountain Chocolate Factory
AbbVie, RTX and IBM headline Zacks??? top analyst picks after strong earnings beats and solid backlog, cloud and AI-driven momentum.
AbbVie Down Since Q4 Earnings Report: How to Play the Stock
ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.
AbbVie: Dominating Immunology While Building Oncology Upside
None of the Big Pharma players has succeeded in challenging AbbVie's dominance in the immune-mediated inflammatory diseases market. In my view, this is directly related to the near-perfect complementarity of Rinvoq and Skyrizi, spanning indications, routes of administration, and mechanisms of action. The total net revenues of this 'duo' were about $25.87 billion in 2025, up 46.2% from 2024.
